Jubilant Ingrevia Q1 Results FY27: Net Profit Rises 40.9% to Rs 105.8 Crore on Strong Specialty Chemicals Demand

Jubilant Ingrevia Q1 results FY27 were announced on Wednesday, 22 July 2026, with the company reporting the numbers summarised below on a consolidated basis for the quarter ended 30 June 2026.

Shares of Jubilant Ingrevia fell 2.32 to Rs 746.10 on the NSE on the results day. The specialty chemicals and nutrition and health solutions maker delivered accelerating growth across the P&L, with profit growth outpacing both revenue and EBITDA.

Click Here – Get Free Investment Predictions

Jubilant Ingrevia Q1 Results FY27 Key Takeaways

Here are the most important numbers from the June 2026 quarter at a glance.

• Revenue: Rs 1,300 Cr in Q1 FY27 versus Rs 1,038 Cr in Q1 FY26, up 25.2% year on year.
• EBITDA: Rs 198.4 Cr in Q1 FY27 versus Rs 142.4 Cr in Q1 FY26, up 39.3% year on year.
• Net Profit (PAT): Rs 105.8 Cr in Q1 FY27 versus Rs 75.1 Cr in Q1 FY26, up 40.9% year on year.
• Jubilant Ingrevia share price fell 2.32 to Rs 746.10 on the NSE on the results day.

Jubilant Ingrevia Q1 Results FY27 Financial Highlights

The table below summarises the consolidated numbers reported in the Jubilant Ingrevia Q1 results FY27 against the year ago quarter.

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 1,300 Cr	Rs 1,038 Cr	+25.2%
EBITDA	Rs 198.4 Cr	Rs 142.4 Cr	+39.3%
Net Profit (PAT)	Rs 105.8 Cr	Rs 75.1 Cr	+40.9%

All figures are on a consolidated basis as reported for the quarter ended 30 June 2026.

Jubilant Ingrevia Q1 Results FY27 Performance Analysis

Get Personalised Guidance from a SEBI-Registered Investment Advisor

The Jubilant Ingrevia Q1 results FY27 show a clean pattern of operating leverage. Revenue grew 25.2%, EBITDA grew faster at 39.3%, and net profit grew fastest at 40.9%, with the EBITDA margin expanding to 15.3% from 13.7%, confirming the growth converted efficiently into profit.

Jubilant Ingrevia operates across specialty chemicals, nutrition and health solutions, and life science chemicals, and growth of this magnitude in the Jubilant Ingrevia Q1 results FY27 likely reflects a combination of volume growth and better pricing or product mix across these segments, alongside possible input cost tailwinds supporting the margin expansion.

The modest 2.32% stock decline despite the strong beat is a mild divergence that may reflect broader market sentiment on the results day, given the chemicals sector saw mixed reactions across several names reporting results this week.

Jubilant Ingrevia Q1 Results FY27: Key Business Factors

1. Broad Based Operating Leverage

Revenue, EBITDA and PAT all accelerated in the Jubilant Ingrevia Q1 results FY27, from 25.2% to 39.3% to 40.9% respectively, a clean signal of margin expansion alongside genuine volume growth.

2. Diversified Specialty Chemicals Portfolio

The company's exposure across specialty chemicals, nutrition and health solutions, and life science chemicals provides some diversification against single category demand swings.

3. Margin Expansion to 15.3%

The EBITDA margin improving to 15.3% from 13.7% in the Jubilant Ingrevia Q1 results FY27 shows the company capturing more value per unit of revenue, whether through cost efficiency or a richer product mix.

Dividend Details

Any dividend announcement accompanying the June 2026 quarter results will be reflected in the company's official NSE and BSE filings. Investors should rely on those filings for dividend confirmation rather than secondary sources.

Jubilant Ingrevia Q1 Results FY27 Outlook for the Full Year

After the Jubilant Ingrevia Q1 results FY27, the key question for FY27 is whether the margin expansion trajectory can continue as the specialty chemicals cycle evolves, and whether demand across the company's diversified end markets remains supportive. Continued volume growth alongside margin discipline would extend the current trend.

Jubilant Ingrevia Stock Performance After the Q1 Results

Download the Univest iOS App or Univest Android App to track Jubilant Ingrevia live share price and upcoming quarterly results.

Jubilant Ingrevia share price fell 2.32 to Rs 746.10 on the NSE after the Jubilant Ingrevia Q1 results FY27, as the market weighed the quarter's numbers.

Investors can compare the trend of the counter with the Nifty 500 index to judge how the stock is placed relative to the broader market after the June quarter results.

Key Risks

Investors going through the fine print of the Jubilant Ingrevia Q1 results FY27 should also weigh the following risks.

1. Chemicals Sector Cyclicality

The specialty chemicals sector can be cyclical, tied to both domestic and export demand cycles, and the strong growth in the Jubilant Ingrevia Q1 results FY27 needs to be viewed against this backdrop.

2. Input Cost Volatility

As a chemicals manufacturer, the company remains exposed to raw material cost swings that can affect margins if not managed through pricing or hedging.

3. Sustaining the Pace of Margin Expansion

With EBITDA margin already up meaningfully this quarter, sustaining further expansion at the same pace may become more challenging in coming quarters.

Conclusion

Jubilant Ingrevia Q1 results FY27 show net profit up 40.9% at Rs 105.8 crore with revenue up 25.2% and the EBITDA margin expanding to 15.3%, a broad based beat across the specialty chemicals business. Investors should track margin sustainability into FY27 and consult a SEBI-registered advisor before acting on the numbers.

Frequently Asked Questions on Jubilant Ingrevia Q1 Results FY27

When were the Jubilant Ingrevia Q1 results FY27 announced?

Ans. The Jubilant Ingrevia Q1 results FY27 were announced on Wednesday, 22 July 2026, for the quarter ended 30 June 2026, on a consolidated basis.

What is the PAT in the Jubilant Ingrevia Q1 results FY27?

Ans. The consolidated PAT in the Jubilant Ingrevia Q1 results FY27 stood at Rs 105.8 crore, up 40.9% from Rs 75.1 crore in Q1 FY26.

What was the revenue in the Jubilant Ingrevia Q1 results FY27?

Ans. Revenue in the Jubilant Ingrevia Q1 results FY27 stood at Rs 1,300 crore, up 25.2% from Rs 1,038 crore in Q1 FY26.

What was the EBITDA margin in the Jubilant Ingrevia Q1 results FY27?

Ans. The EBITDA margin in the Jubilant Ingrevia Q1 results FY27 expanded to 15.3% from 13.7% in Q1 FY26, with EBITDA up 39.3% to Rs 198.4 crore.

What businesses does Jubilant Ingrevia operate?

Ans. The company operates across specialty chemicals, nutrition and health solutions, and life science chemicals segments.

How did the share price react to the Jubilant Ingrevia Q1 results FY27?

Ans. Jubilant Ingrevia share price fell 2.32% to Rs 746.10 on the NSE after the Jubilant Ingrevia Q1 results FY27.

Is the stock a good buy after the Jubilant Ingrevia Q1 results FY27?

Ans. The Jubilant Ingrevia Q1 results FY27 show a broad based beat with accelerating growth down the P&L, though chemicals sector cyclicality is a factor to weigh. This article is for educational purposes only. Consult a SEBI-registered advisor before investing.

Where can I verify the Jubilant Ingrevia Q1 results FY27?

Ans. The official filings for the June 2026 quarter are available on the NSE and BSE websites, and the stock can be tracked on the Univest app.